GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

IPOBIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025 06.02.2025 / 07:00 CET/CEST__________THIS IS A RESTRICTED ...

GSK plc (NYSE:GSK – Get Free Report) gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $34.84, but opened at $37.06.

A task force has been set up to look into how to spend a £2m GSK legacy as the pharmaceutical giant closes its doors in Ulverston. Giles ...

The stock market extended its winning streak on Wednesday, closing firmer as investors seemed to have already priced in the ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GSK PLC. (GSK), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...